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Abstract
Restrictive policies on access to new, curative hepatitis C treatments represent a substantial barrier 
to treating patients infected with hepatitis C. This case series demonstrates challenges experienced 
by patients and practitioners in accessing these treatments and highlights several strategies for 
navigating the treatment preauthorization process.
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Background
In the United States, hepatitis C virus (HCV) infection is a leading cause of liver-related 
deaths, cirrhosis, and hepatocellular carcinoma.1 Infection is primarily acquired through 
percutaneous blood exposure, including injection drug use and historically contaminated 
blood products, which has led to the greatest prevalence among individuals born from 1945 
through 1965.1 Individuals chronically infected with HCV require ongoing monitoring to 
assess for progression of liver fibrosis, classified according to the Metavir histological scores 
of F0 to F4. A Metavir score of F0 indicates no fibrosis and a score of F4 indicates cirrhosis. 
HCV treatments were historically used sparingly because of toxic effects and modest 
efficacy.1 However, since 2013, highly effective, safe, and curative peginterferon alfa–
sparing direct-acting antiviral (DAA) drugs for HCV have been available, increasing the 
number of individuals willing and able to be treated.1
Although new DAAs are becoming available and costs are continuing to decline, the initial 
retail costs of $83,000 to $153,000 per treatment course prompted health plans and payers to 
institute restrictive policies and preauthorization procedures for treatment.2–4 Health plan 
and payer policies vary but have often included restrictions based on liver fibrosis stage, 
documented alcohol and drug abstinence, and the practitioner’s clinical specialty.2,4 High 
drug costs, in addition to restrictive policies, limit treatment access and create a substantial 
barrier to curing the 3.5 million people estimated to be chronically infected with HCV in the 
United States.3–5 Currently, patient access to HCV treatment requires health care 
practitioners and staff to expertly navigate a complex authorization process.
The Centers for Disease Control and Prevention (CDC) Hepatitis C Community-based Test 
and Cure Project supports clinical and public health partners with improving HCV testing, 
linkage to care, and treatment activities in Baltimore, Maryland; Chicago, Illinois; and 
Seattle–King County, Washington. This case series presents examples from each partner site 
to illustrate challenges in obtaining HCV treatment for patients with private or public 
insurance undergoing routine clinical care. All patients mentioned in this case series gave 
their consent to be included.
Baltimore, Maryland
Patient A is a 55-year-old man with a history of chronic HCV genotype 1a infection, a 
Metavir score of F4 (cirrhosis), depressive disorder, traumatic brain injury, and alcohol use 
disorder. He is insured through a Medicaid managed care organization.
His primary care practitioner prescribed sofosbuvir/ledipasvir (slash indicates a 
coformulation) in January 2016; however, the managed care organization immediately 
denied the preauthorization because of an isolated episode of excessive drinking in 2014. 
His practitioner determined the drinking episode documented in the medical record was 
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erroneous and in a written appeal provided evidence of patient A’s abstinence from alcohol. 
The appeal was denied, and the physician filed a second one directly to the managed care 
organization’s chief medical officer. Estimated staff time spent on the approval process 
totaled 4 hours. The preauthorization was approved on March 2, 2016, and patient A 
initiated treatment on May 4, 2016, which was approximately 3 to 4 months after the 
treatment was prescribed. He had an undetectable viral load 4 weeks after treatment 
initiation, but did not return for follow-up care. Efforts to reengage him in care have been 
unsuccessful.
Chicago, Illinois
Patient B is a 60-year-old man with chronic HCV genotype 3a infection and a Metavir score 
of F4 (cirrhosis). He had a history of alcohol and illicit drug use and has been abstinent for 
11 years. He has employer-based private insurance, which restricts HCV medication to 
patients having a Metavir score of F2 or greater.
Patient B enrolled in the Hepatitis C Community Alliance for Testing and Treatment case 
management program in Chicago in July 2015 for assistance in obtaining HCV treatment. At 
that time, no effective peginterferon alfa–sparing therapy for individuals with HCV genotype 
3a infections with cirrhosis was available. Patient B was advised to defer treatment until 
daclatasvir received US Food and Drug Administration (FDA) approval so he could receive 
a more efficacious peginterferon alfa–sparing regimen. Daclatasvir was licensed 
approximately 1 month after he enrolled in the program, and the preauthorization was 
submitted for 16 weeks of daclatasvir, sofosbuvir, and ribavirin. Preauthorization was denied 
because daclatasvir would not be available on the insurance company’s formulary for 6 
months. Attempts to obtain the medication more quickly through the pharmaceutical 
company’s patient assistance program were unsuccessful.
In January 2016, after daclatasvir was added to the formulary, the patient’s 
gastroenterologist submitted a new preauthorization request for the medication that was 
approved, and he initiated treatment in March 2016, 7 months after the initial 
preauthorization request was submitted. In April 2016, his prescription benefits carrier 
changed, necessitating a new preauthorization for the remaining 12 weeks of the then 
adjusted 24-week treatment schedule. In total, the estimated staff time for all 
preauthorization processes was 40 hours. The new preauthorization was approved and 
patient B completed treatment. In November 2016, 12 weeks after the end of therapy, he had 
a sustained virologic response (SVR).
Seattle–King County, Washington
Patient C is a 58-year-old man with chronic HCV genotype 1b infection. His liver fibrosis 
was assessed as F0–F1 in 2012 and F1 in 2014 using serum biomarker testing. He had 
previously used injection drugs but had been abstinent since 2006. The patient also reported 
abstinence from alcohol since 2010. He was insured through a Medicaid managed care 
organization.
In December 2014, he was seen by a specialist and found to have a transient elastography 
score of 1.56 m/s, corresponding to Metavir scores F2–F3. At that time, he was prescribed 
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sofosbuvir/ledipasvir, but the preauthorization request was denied because the payer stated 
he did not satisfy the fibrosis criteria of F3 and greater (A fibrosis criteria of ≥F3 was 
previously required by Washington State Medicaid for HCV treatment authorization. The 
requirement was removed in June 2016 after a legal challenge). His insurance status made 
him ineligible for the pharmaceutical company’s patient assistance program. After 14 
months, an estimated 20 hours of staff time, and numerous appeals by pharmacists at the 
specialty clinic, Medicaid authorized the prescription. In February 2016, he initiated 
sofosbuvir/ledipasvir and successfully completed the 12-week course of therapy in June 
2016. In October 2016, 12 weeks after the end of therapy, he had an undetectable viral load.
Discussion
At present, increasing access to HCV treatment requires overcoming numerous barriers at 
the levels of the health care system, clinic and practitioner, and patient, as shown in the Box. 
Health care system barriers are generally related to the high initial list prices of HCV 
medications and efforts by health plans and payers to control costs through preauthorization 
requirements. These requirements, which have been amply described,3,4,6 can create 
impediments to treatment access. A study of 2321 patients in 4 states showed that 46% were 
denied Medicaid payments even after appeal, compared with 10% of patients with private 
insurance.7 Changes in drug prices and health plan and payer restrictions have resulted in 
fewer denials in subsequent studies.5,8 However, the burden of these denials falls 
disproportionally on publicly insured and marginalized populations, resulting in systematic 
obstacles to HCV treatment access for vulnerable people.6 In addition, as the cases above 
illustrate, even if individuals eventually gain access to treatment, burdensome 
preauthorization requirements divert staff time from patient care and limit the ability of 
practitioners to scale up treatment initiation for HCV-infected individuals. At the clinic and 
practitioner level, barriers to treatment access include not testing for anti-HCV antibody 
(despite recommendations from guidelines), clinic referral practices, and extent of a 
practitioner’s knowledge of HCV treatments. Not testing for anti-HCV antibody 
appropriately based on recommended guidelines, for instance, or not obtaining confirmatory 
RNA testing represents a substantial hurdle to HCV treatment access because a lack of 
diagnosis precludes access to treatment.9–12 The impact of this barrier can be reduced by 
various interventions such as the use of electronic medical records and clinical decision 
tools, reflex RNA testing, and patient navigators.10,11,13 Also, individual practitioners may 
lack familiarity with new HCV treatments. Although current HCV treatment regimens are 
considered simple to manage compared with peginterferon alfa–based regimens, a survey of 
practitioners found that 70% did not feel sufficiently knowledgeable about HCV treatment, 
and 71% refer persons with HCV to subspecialty care.11 This knowledge gap can be 
addressed through training, and primary care physicians have been shown to have treatment 
outcomes similar to those of subspecialists.14 Although referrals to subspecialists for HCV 
treatment may be required by certain health plans and payers,4,11 this may cause individuals 
to be lost to follow-up and unable to access treatment. This barrier can be addressed through 
interventions such as patient navigators and colocation of services, or it can be removed 
completely by enabling primary care clinicians to prescribe HCV treatments independently 
or through comanagement with a specialist.10,11,13 Finally, at the patient level, individuals 
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without health care access, either due to no linkage to care, lack of insurance, or being 
underinsured, will likely be unable to receive HCV treatment.
As illustrated by this case series, persons who live with HCV infection, whether privately or 
publicly insured, face numerous challenges in accessing treatments. The time from treatment 
decision to treatment initiation in these cases took as long as 16 months and generally 
involved denials of initial preauthorization. Do and colleagues examined drug authorizations 
for sofosbuvir/ledipasvir among publicly and privately insured individuals and found 18.6% 
of initial preauthorizations were not approved.8 Overall, the average time-to-decision on the 
initial preauthorization was 26.1 days (standard deviation [SD], 25.2 days), and the decision 
on appeal required an additional 18.6 days on average (SD, 22.1 days). Although the 
majority of patients eventually received therapy based on appeal, unnecessary treatment 
delays occurred because the initial preauthorization was denied. In total, 4.7% of patients 
were ultimately denied therapy.8 Similarly, Younossi and colleagues found that among 3841 
patients prescribed a sofosbuvir-containing regimen, 315 (8%) did not start therapy; 81% of 
the nonstarts were due to insurance-related processes and financial reasons even among 
those with Metavir fibrosis scores of F3 and greater.5 In addition, Younossi and colleagues 
reported that although 10% of the total study population had Medicaid coverage, 43% of the 
315 nonstart patients were in the Medicaid-covered population.5 Overall, those with private 
insurance were approximately 6.5 times more likely to receive treatment than a propensity 
score–matched group of those with Medicaid.5 The current approval process for HCV 
treatments can be unpredictable and burdensome for clinic staff, and the reasons for denial 
may not be clinically based.1,3,4
Although treatment of HCV-infected individuals is cost-effective from a societal 
perspective,15 the high cost of HCV therapy is a budgetary issue for state Medicaid 
programs on 1- to 2-year cycles. In 2014, as much as 6.7% of state Medicaid prescription 
drug spending was attributable to HCV treatment.16 Fortunately, the entry of new DAAs into 
the market, mandated 23% rebates for HCV-infected patients on Medicaid, and negotiated 
price reduction by payers have lowered the cost of HCV medications.3,17 In addition, in 
November 2015, the Centers for Medicare and Medicaid Services (CMS) notified states that 
limitations on coverage “should not result in the denial of access to effective, clinically 
appropriate, and medically necessary treatments using DAA drugs” for HCV-infected 
persons.18 This should prompt health plans and payers to reevaluate current restrictive 
reimbursement policies. In fact, some health plans and payers have revised coverage policies 
to remove previous authorization requirements, some of which were prompted by successful 
legal challenges such as the one in Washington state.19,20 At this time, it is too early to 
evaluate the long-term impact of these changes on the preauthorization process; however, 
they will likely improve treatment access for individuals covered by these health plans and 
payers.
Regardless of health plan and payer decisions to reevaluate coverage policies, health care 
practitioners will still be responsible for prescribing HCV treatment and obtaining necessary 
preauthorization. Several strategies can be used to assist with preauthorization. Case 
managers can serve as a useful resource for patient support and for navigating an appeals 
process. Specialty pharmacies and in-clinic pharmacy support or pharmacy benefits 
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managers, if available, may also be a resource for assisting health care practitioners in 
successfully completing the approval and appeal processes. Additional training for primary 
care practitioners to become specialized HCV care clinicians can expand the number of 
practitioners able to prescribe HCV treatment in areas where health plans and payers restrict 
by specialty. All of these strategies incur costs but not necessarily to the third-party payer. 
Finally, advocacy groups such as the National Viral Hepatitis Roundtable have developed 
and compiled resources for health care practitioners, including checklists and guides for 
initiating HCV treatment and template letters for appealing insurance denials, to reduce the 
administrative burden on practitioners.21
This case series has several limitations. It reflects individual patient experiences and should 
not be considered representative of HCV treatment access for all health plans or payers, 
including Medicare. Uninsured individuals, who may be eligible for treatment access 
through patient assistance programs at pharmaceutical companies, were also not included. 
Finally, policies regarding preauthorization requirements and treatment access are not static. 
Although policy changes may be expected to increase treatment access, such as the 
Washington state ruling in 2016, the long-term impact of this specific change and others on 
the preauthorization process cannot be formally evaluated at this time.
Despite a decrease in the price of HCV medications, access to HCV treatment remains a 
barrier to reducing HCV-associated morbidity and mortality. In addition to decreases in the 
costs of HCV medications, health plans and payers should reevaluate restrictive criteria that 
limit access to HCV treatment.
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Barriers to Hepatitis C Treatment Access in the United States
• System-Level Barriers
– Cost of drugs
– Health plan and payer restrictions/Preauthorization requirements
• Clinic- and Practitioner-Level Barriers
– Deficiencies in testing for anti-HCV antibody and confirmation of 
diagnosis
– Lack of practitioner familiarity with treatment
– Referral to subspecialty practitioners and loss to follow-up
• Patient-Level Barrier
– Lack of health care access
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